Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial

Nina Shah, Nikhil C. Munshi, Jesús G. Berdeja, Sundar Jagannath, Olivia Finney, Nathan Martin, Amit Agarwal, Everton Rowe, Timothy B. Campbell, Jesús F. San-Miguel

Blood (2021) 138 (Supplement 1): 1739.

https://doi.org/10.1182/blood-2021-148375

Published: 2021

Journal Articles

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

Noopur S. Raje, Nina Shah, Sundar Jagannath, Jonathan L. Kaufman, David S. Siegel, Nikhil C. Munshi, Jacalyn Rosenblatt, Yi Lin, Andrzej Jakubowiak, Alison Timm, Ashish Yeri, Nathan Martin, Timothy B. Campbell, Olivia Finney, Anna Truppel-Hartmann, Fabio Petrocca, Jesús G. Berdeja, Melissa Alsina

Blood (2021) 138 (Supplement 1): 548.

https://doi.org/10.1182/blood-2021-146518

Published: 2021

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121) Responses Are Characterized By Early and Temporally Consistent Activation and Expansion of CAR T Cells with a T Effector Phenotype

Nathan Martin, PhD, Ethan G. Thompson, PhD, Will Brown, MS, Olivia Finney, PhD, Julie Rytlewski, PhD, Yue Jiang, PhD, Dipen Sangurdekar, PhD, Julie Wang, PharmD, PhD, Hans Bitter, PhD, Ronald J. Hause, Jr., PhD, Timothy B. Campbell, MD PhD, Kristen Hege, MD, Shari Kaiser, PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-134378

Published: 2020

Journal Articles

Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma

Julie Rytlewski, PhD, Deepu Madduri, MD, Jaymes Fuller, PhD, Timothy B. Campbell, MD PhD, Afshin Mashadi-Hossein, MSc, Ethan G. Thompson, PhD, Yue Jiang, PhD, Nathan Martin, PhD, Dipen Sangurdekar, PhD, Olivia Finney, PhD, Hans Bitter, PhD, Amit Agarwal, MD PhD, Shari Kaiser, PhD, Kristen Hege, MD, Ronald J. Hause, Jr., PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-134369

Published: 2020

Journal Articles

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

Ethan G. Thompson, PhD, Yue Jiang, PhD, Timothy B. Campbell, MD PhD, Jaymes Fuller, PhD, Shari Kaiser, PhD, Afshin Mashadi-Hossein, MSc, Julie Rytlewski, PhD, Nathan Martin, PhD, Olivia Finney, PhD, Katja Kleinsteuber, PhD, Eric Alonzo, PhD, Chetanya Pandya, PhD, Amit Agarwal, MD PhD, Kristen Hege, Noopur S. Raje, MD, Nikhil C. Munshi, MD, Ronald J. Hause, PhD

Blood (2019) 134 (Supplement_1): 4328.

https://doi.org/10.1182/blood-2019-124998

Published: 2019

Journal Articles

Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells

Julie Rivers, MD, Colleen Annesley, MD, Corinne Summers, MD, Olivia Finney, PhD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2018) 132 (Supplement 1): 2957.

https://doi.org/10.1182/blood-2018-99-113744

Published: 2018

Journal Articles

Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy

Francesco Ceppi, MD, Colleen Annesley, MD, Olivia Finney, PhD, Corinne Summers, MD, Stephanie Rhea, BS, Isaac C. Jenkins, MS, Qian V. Wu, PhD, Wen Yang, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie R. Park, MD, Rebecca Gardner, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2018-99-110164

Published: 2018

Journal Articles

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Colleen Annesley, MD, Rebecca Gardner, MD, Olivia Finney, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4021.

https://doi.org/10.1182/blood-2018-99-112285

Published: 2018

Journal Articles

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

Rebecca Gardner, MD, Olivia Finney, PhD, Hannah Brakke, MS, Stephanie Rhea, BS, Roxana Hicks, BS, Danielle Doolittle, Marisa Lopez, Rimas J Orentas, PhD, Daniel Li, PhD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4022.

https://doi.org/10.1182/blood-2018-99-117493

Published: 2018

Journal Articles

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

Rebecca Gardner, MD, Colleen Annesley, MD, Olivia Finney, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Kaelin Crews, Lauren Huang, Christopher Brown, Stephanie Mgebroff, Catherine Lindgren, Karen Spratt, PhD, Josh Gustafson, PhD, Adam Johnson, PhD, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 278.

https://doi.org/10.1182/blood-2018-99-113126

Published: 2018

Journal Articles

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Rebecca A. Gardner, Olivia Finney, Colleen Annesley, Hannah Brakke, Corinne Summers, Kasey Leger, Marie Bleakley, Christopher Brown, Stephanie Mgebroff, Karen S. Kelly-Spratt, Virginia Hoglund, Catherine Lindgren, Assaf P. Oron, Daniel Li, Stanley R. Riddell, Julie R. Park, Michael C. Jensen

Blood (2017) 129 (25): 3322–3331.

https://doi.org/10.1182/blood-2017-02-769208

Published: 2017

Includes: Supplemental data

Journal Articles

CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL

Rebecca Gardner, MD, Olivia Finney, PhD, Hannah Smithers, MS, Kasey J Leger, MD MSc, Colleen E. Annesley, MD, Corinne Summers, MD, Christopher Brown, Stephanie Mgebroff, MS, Catherine Lindgren, Karen Spratt, PhD, Assaf Oron, PhD, Daniel Li, PhD, Marie Bleakley, MDPhD, Julie R Park, MD, Michael C Jensen, MD

Blood (2016) 128 (22): 219.

https://doi.org/10.1182/blood.V128.22.219.219

Published: 2016

Journal Articles

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

Rebecca Gardner, MD, Kasey J Leger, MD MSc, Colleen E. Annesley, MD, Corinne Summers, MD, Julie Rivers, MD, Juliane Gust, MD, Katherine Tarlock, MD, Todd M Cooper, DO, Navin R. Pinto, MD, Olivia Finney, PhD, Hannah Smithers, MS, Assaf Oron, PhD, Daniel Li, PhD, Julie R Park, MD, Michael C Jensen, MD

Blood (2016) 128 (22): 586.

https://doi.org/10.1182/blood.V128.22.586.586

Published: 2016

Journal Articles

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL -rearranged B-ALL from CD19 CAR-T-cell therapy

Rebecca Gardner, David Wu, Sindhu Cherian, Min Fang, Laïla-Aïcha Hanafi, Olivia Finney, Hannah Smithers, Michael C. Jensen, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2016) 127 (20): 2406–2410.

https://doi.org/10.1182/blood-2015-08-665547

Published: 2016

Journal Articles

T Cell Products of Defined CD4:CD8 Composition and Prescribed Levels of CD19CAR/Egfrt Transgene Expression Mediate Regression of Acute Lymphoblastic Leukemia in the Setting of Post-Allohsct Relapse

Rebecca A Gardner, MD, Julie R Park, MD, Karen S Kelly-Spratt, PhD, Olivia Finney, PhD, Hannah Smithers, Virginia Hoglund, Christopher Brown, Stephanie Mgebroff, MS, Catherine G. Lindgren, Assaf P Oron, PhD, Marie Bleakley, MD, Michael C Jensen, MD

Blood (2014) 124 (21): 3711.

https://doi.org/10.1182/blood.V124.21.3711.3711

Published: 2014

NARROW

Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

Idecabtagene Vicleucel (ide-cel, bb2121) Responses Are Characterized By Early and Temporally Consistent Activation and Expansion of CAR T Cells with a T Effector Phenotype

Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells

Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL -rearranged B-ALL from CD19 CAR-T-cell therapy

T Cell Products of Defined CD4:CD8 Composition and Prescribed Levels of CD19CAR/Egfrt Transgene Expression Mediate Regression of Acute Lymphoblastic Leukemia in the Setting of Post-Allohsct Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only